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Abstract Evolving debate suggests that C-reactive protein
(CRP) might be associated with the development of venous
thromboembolism (VTE); however, the evidence is con-
flicting. We aimed to assess the prospective association of
CRP with VTE risk. C-reactive protein was measured in
serum samples at baseline from 2420 men aged
42–61 years, from the Kuopio Ischemic Heart Disease
study. Within-person variability in CRP levels was cor-
rected for using repeat measurements of CRP taken
11 years after baseline. Incident VTE events (n = 119)
were recorded during a median follow-up of 24.7 years.
The age-adjusted regression dilution ratio for loge CRP was
0.57 [95% confidence interval (CIs): 0.51–0.64]. In age-
adjusted Cox regression analysis, the hazard ratio (95%
CIs) for VTE per 1 standard deviation (SD) increase in loge
baseline CRP was 1.17 (0.98–1.40). Further adjustment for
several established and emerging risk factors did not alter
the association. In a meta-analysis of nine population-based
studies (including the current study) comprising 81,625
participants and 2225 VTE cases, the fully-adjusted risk
estimate for VTE was 1.14 (1.08–1.19) per SD increase in
loge baseline CRP. In a pooled dose–response analysis, a
linear association between CRP and VTE risk was sug-
gested (P for nonlinearity = 0.272). The pooled risk esti-
mate for VTE per 5 mg/l increment in CRP levels was 1.23
(1.09–1.38). C-reactive protein was only modestly associ-
ated with VTE risk in the primary analysis. Pooled evi-
dence, however, suggests that elevated CRP is associated
with greater VTE risk, consistent with a linear dose–re-
sponse relationship.
Keywords C-reactive protein  Cohort study  Venous
thromboembolism  Deep vein thrombosis  Pulmonary
embolism
Introduction
Venous thromboembolism (VTE), which comprises of
deep vein thrombosis (DVT) and pulmonary embolism
(PE), affects several millions of people and is an important
cause of morbidity, mortality and increasing health care
costs globally [1]. Despite advances in treatment options,
VTE remains a global public health problem [2] and there
has been no decrease in its incidence for the past several
decades. Anticoagulation, which is the mainstay of VTE
treatment, is commonly associated with an increased risk of
major bleeding and subsequently high case fatality rates
[3]. Major risk factors for VTE include immobilisation,
trauma, surgery, hormonal therapy, obesity, and disorders
of hypercoagulation [4]. However, in a substantial number
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of VTE cases, the causes are unknown [5]. It therefore
appears that there may be several unknown factors
involved in the pathogenesis of VTE. Identification of risk
factors of VTE which have predictive or causal relevance
could aid in the development of preventive strategies,
especially in high risk individuals.
C-reactive protein (CRP), a non-specific marker for
inflammation which is produced by the liver, is known to
play a central role in the aetiopathogenesis of arterial
atherothrombosis [6]. Cardiovascular disease (CVD) and
VTE are closely linked [7–9] and share common ante-
cedent risk factors [10], and there is an evolving debate that
inflammation or CRP might also be linked to the devel-
opment of VTE [11, 12]; however, the emerging evidence
is controversial. A number of population-based prospective
cohort studies have reported on the associations of circu-
lating levels of CRP with subsequent risk of VTE, but the
results have been conflicting. Whereas majority of studies
have shown no evidence of any associations [13–16], only
a few studies have reported some evidence of an associa-
tion between CRP and VTE risk [17–19]. Given that CRP
is known to exert prothrombotic effects and is closely
linked with several risk factors for VTE [20–22], we
hypothesized that increased baseline circulating levels of
CRP will be associated with subsequent risk of VTE. In
this context, we aimed to evaluate the nature and magni-
tude of the prospective association of CRP with risk of
VTE in a population-based cohort of 2420 men with no
previous history of VTE from eastern Finland.
Repeat measurements of CRP performed several years
apart in a random sample of participants enabled quantifi-
cation of within-person variability in CRP levels. Finally,
with the availability of a number of published articles that
have evaluated the prospective association between CRP
and VTE, this offered the opportunity to perform a sys-
tematic review and meta-analysis, thereby re-evaluating
the nature and magnitude of the association in a larger
representative sample of participants and VTE cases.
Methods
We conducted this study in accordance with STROBE
(STrengthening the Reporting of OBservational studies in
Epidemiology) guidelines for reporting observational
studies in epidemiology (Appendix 1).
Study design and participants
Participants included in this analysis were part of the
Kuopio Ischemic Heart Disease (KIHD) study, a single-
centre, population-based prospective cohort study, which
was set up to evaluate risk factors for CVD and other
chronic disease outcomes. The study design and recruit-
ment methods have been described previously [23, 24]. A
representative sample of men aged 42–61 years who were
inhabitants of the city of Kuo-pio and its surrounding rural
communities in eastern Finland were invited for baseline
examinations carried out between March 1984 and
December 1989. A total of 3433 potentially eligible men
were randomly selected and of this number, 3235 were
found to be eligible. Among the eligible men, 2682 (78%)
provided consent to participate in the study; 186 did not
respond to the invitation and 367 declined to participate in
the research study. In total, 2420 men who had complete
information on CRP, relevant covariates, and VTE out-
comes were included in the final analyses. All study pro-
cedures were approved by the Research Ethics Committee
of the University of Eastern Finland and were conducted
according to the Declaration of Helsinki. Written informed
consent was provided by each participant.
Assessment of risk markers
Baseline informationwas collected by physical examination,
blood samples, and self-administered questionnaires. Blood
pressure was recorded by an experienced nurse with a ran-
dom-zero sphygmomanometer (Hawskley, UK) after 5 and
10 min of rest in a seated position [25]. Body mass index
(BMI) was estimated as weight in kilograms divided by the
square of height in meters. Blood samples were taken after 8
and 10 a.m. after an overnight fast. In addition, participants
were to abstain from alcohol consumption for at least 3 days
and smoking for at least 12 h prior to blood collection. Serum
samples were stored frozen at-80 C before measurements
of lipids and biochemical analytes. Serum CRP measure-
ments were made with an immunometric assay (Immulite
High Sensitivity C-Reactive Protein Assay; DPC, Los
Angeles, CA, USA), with repeat measurements performed in
a random subset of participants at 11 years after the baseline
measurements. The kinetic method (Thermo Fisher Scien-
tific, Vantaa, Finland) was used to measure gamma-glu-
tamyltransferase (GGT) activity. Fasting plasma glucose
(FPG) was measured using the glucose dehydrogenase
method (Merck, Darmstadt, Germany). For the assessments
of age, smoking, alcohol consumption, baseline medical
conditions, and medication history; participants completed
self-administered health and lifestyle questionnaires [26].
The energy expenditure of physical activity was assessed
using the validated KIHD 12-month leisure-time physical
activity questionnaire [27, 28].
Ascertainment of incident venous thromboembolism
All first lifetime VTE events that occurred from study entry
to 2013 were included and were identified by searching the
S. K. Kunutsor et al.
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National Hospital Discharge Registry data by computer
linkage and a comprehensive review of available hospital
records, wards of health centres, health practitioner ques-
tionnaires, death certificate registers, autopsy registers, and
medico-legal reports. No losses to follow-up were recorded
as all participants in the KIHD study (using Finnish per-
sonal identification codes) are under continuous surveil-
lance for the development of new outcomes including VTE
cases. Documents were cross-checked in detail and VTE
events were validated by two physicians. The diagnosis of
DVT or PE required positive imaging tests.
Statistical analyses
Prospective cohort analyses
Skewed variables (CRP, triglycerides, and GGT) were log
transformed to achieve approximately normal distributions.
Descriptive analyses were conducted to summarize base-
line characteristics of participants, with means (SD) or
medians (IQR, interquartile range) reported for continuous
variables and percentages for categorical variables. Time-
to-event analyses were conducted using Cox proportional
hazard regression models after confirming assumptions of
proportionality of hazards using Schoenfeld residuals [29].
To quantify and correct for within-person variability in
CRP levels, which is, the extent to which an individual’s
CRP measurements vary around the long-term average
exposure levels (‘‘usual levels’’) [30], adjusted regression
dilution ratios (RDRs) were estimated by regressing
available repeat measurements on baseline values [31]. The
RDR assumes that the ‘‘usual levels’’ of CRP represents the
true long-term exposure of CRP levels on VTE risk. To
characterize the shape of the association between CRP and
VTE risk, hazard ratios (HRs) were calculated within
quartiles of baseline CRP levels and plotted against mean
CRP levels within each quartile using floating absolute
risks [26]. C-reactive protein was modeled continuously
[per 1 standard deviation (SD) higher loge CRP levels] and
as categories (quartiles) defined according to the baseline
distribution of CRP levels. The SD of baseline loge CRP
was 0.97 (equivalent to approximately three-fold higher
circulating CRP, as e0.97 = 2.64). The HRs were adjusted
progressively for (1) age; and (2) other established risk
factors and potential confounders [BMI, systolic blood
pressure (SBP), history of hypertension, prevalent coronary
heart disease (CHD), smoking status, history of diabetes,
total cholesterol, lipid medication, physical activity, and
GGT]. These confounders were selected based on their
potential as confounders as a result of their known asso-
ciations with VTE outcomes and observed associations
with CRP using the available data [32] or evidence from
previous research. Formal tests of interaction were used to
assess statistical evidence of effect modification by cate-
gories of pre-specified clinically relevant individual level
characteristics.
Systematic review and meta-analysis
We conducted a meta-analysis of published studies
reporting on the association between CRP and risk of VTE,
using a predefined protocol and reported in accordance
with PRISMA and MOOSE guidelines [33, 34] (Appen-
dices 2 and 3). Published observational population-based
prospective (cohort, case cohort, or nested case–control)
studies with at least one year of follow-up that evaluated
the associations between baseline levels of CRP and risk of
VTE up to January 2017, were sought using computer-
based databases (MEDLINE, EMBASE, and Web of Sci-
ence). The computer-based searches combined free and
MeSH search terms and combined key words related to the
exposure (e.g., ‘‘C-reactive protein’’) and outcome (e.g.,
‘‘venous thromboembolism’’, ‘‘deep vein thrombosis’’,
‘‘pulmonary embolism’’). We placed no restrictions on
language or the publication date. Details of the search
strategy are reported in Appendix 4. Two independent
authors (S.K.K., S.S.) performed screening, data extraction,
and quality assessments. Discrepancies were discussed and
agreement reached by adjudication of a third author
(J.A.L.). Information was extracted on study characteristics
such as study design, publication year, geographical loca-
tion, baseline age, duration of follow-up, sample size and
number of VTE events, and risk estimates for the most
adjusted models. We assessed study quality using the nine-
star Newcastle–Ottawa Scale (NOS) [35] as described
previously [36]. Summary measures were presented as
relative risks (RRs) with 95% confidence intervals (CIs).
Following Cornfield’s rare disease assumption [37], hazard
ratios and odds ratios were assumed to approximate the
same measure of RR. To enable a consistent approach to
the meta-analysis and enhance comparison with the pri-
mary analysis, reported study-specific risk estimates were
also transformed to per SD increase in or as extreme
quartiles of CRP using standard statistical methods,
[38, 39] which have been described in detail previously
[40, 41] and in Appendix 5. The associations of ‘‘usual
levels’’ of CRP with VTE risk were estimated using the
RDR derived from the KIHD Study. Summary RRs were
pooled using a random effects model to minimize the effect
of between-study heterogeneity [42]. Subsidiary analysis
used fixed effects models. Statistical heterogeneity between
studies was quantified using standard Chi square tests and
the I2 statistic [43]. We also assessed the potential for small
study effects such as publication bias through formal tests,
namely Begg’s funnel plots [44] and Egger’s regression
symmetry test [45].
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We also performed a pooled dose–response association
of circulating levels of CRP with risk of VTE using data
from published studies. A 2-step generalized least-squares
trend estimation (GLST) analysis as described by Green-
land and Orsini [39, 46], was used to compute study-
specific slopes (linear trends) from the correlated natural
logs of the RRs across categories of CRP. Potential non-
linear dose–response relationships were examined by
modeling levels of CRP using restricted cubic splines.
Details of the methodology have been described in previ-
ous reports [41, 47]. Briefly, this method requires that the
number of cases, person-years of follow-up or non-cases,
and the RRs with the variance estimates for at least three
quantitative categories of CRP levels are known. The
median or mean level of CRP for each category was
assigned to each corresponding RR. If data were not
available, we estimated the median using the midpoint of
each category. When the highest or lowest category was
open, we assumed it to be the same amplitude as the
adjacent category. All statistical analyses were conducted
using Stata version 14 (Stata Corp, College Station, Texas).
Results
Baseline characteristics
Table 1 and Appendix 6 summarize the baseline charac-
teristics of the 2420 participants included in the present
analysis according to quartiles of CRP and development of
VTE events during follow-up respectively. The mean age
of study participants was 53 (SD, 5) years. The mean (SD)
loge CRP level was 0.34 (0.97) mg/l. There were no evident
differences in baseline characteristics between VTE cases
and participants who did not develop VTE during follow-
up, except for smoking status. There was a higher pro-
portion of smokers in the group who did not develop VTE
during follow-up compared with the group that developed
VTE during follow-up.
Correction for within-person variability in CRP
levels
In a random subset of 744 participants, repeat measurements
of CRP were taken at 11 years after the baseline measure-
ments during the follow-up period. Overall, the age-adjusted
RDR of loge CRP was 0.57 (95% CI 0.51–0.64), which
suggests that the association of CRP with VTE risk using
baseline measurements of CRP could under-estimate the
association by [(1/0.57)-1] 9 100 = 75%.
C-reactive protein and risk of venous
thromboembolism
Prospective cohort analysis
During a median follow-up of 24.7 (interquartile range
17.1–27.1) years, 119 VTE events (annual rate 2.29/1000
person-years at risk; 95% CI 1.92–2.75) were ascertained. A
trend towards a log-linear association was observed between
CRP and risk of VTE in both age- and multivariate-adjusted
analysis (Appendix 7). The age-adjusted HR for VTE per 1 SD
increase in loge baseline CRP was 1.17 (95% CI 0.98–1.40)
which remainedunchanged1.18 (95%CI0.97–1.44)on further
adjustment for several established risk factors and potential
confounders (BMI, SBP, history of hypertension, prevalent
CHD, smoking status, history of diabetes, total cholesterol,
lipid medication, physical activity, and GGT). Alternatively,
comparing the top versus bottom quartiles of CRP levels, the
correspondingadjustedHRswere 1.39 (95%CI0.84–2.30) and
1.38 (95% CI 0.80–2.39) respectively (Table 2). The corre-
sponding adjusted HRs per 1 SD increase in usual loge CRP
levels were 1.32 (95% CI 0.96–1.80) and 1.34 (95% CI
0.95–1.90) respectively (Table 2). The association did not
importantly vary across several clinical subgroups (P for
interaction C 0.10 for each; Fig. 1).
Meta-analysis of published studies
We identified eight population-based prospective cohort
studies reporting on the associations between circulating
blood CRP and VTE risk (Appendices 8 and 9) [13–19, 48].
Including the current study, the pooled analysis comprised
nine studies involving 81,625 participants and 2225 VTE
cases. The pooled RRs for VTE per 1 SD higher baseline and
usualCRP levels in fully-adjusted analyseswere1.14 (95%CI
1.08–1.19) and 1.25 (95% CI 1.15–1.36) respectively;
(I2 = 0%, 95% CI 0–65%; P = 0.648) (Fig. 2). The corre-
sponding RRs were 1.36 (95% CI 1.20–1.54) and 1.72 (95%
CI 1.38–2.13) respectively when comparing the top versus
bottomquartiles ofCRP levels.Whenafixedeffectmodelwas
employed, the summaryRRswere identical to that of random-
effects meta-analysis. There was no evidence of publication
bias among contributing studies (Egger’s test P = 0.743)
(Appendix 10). In pooled analysis of 4 studies providing rel-
evant data [15–18], we found no evidence of statistically
significant departure from linearity (P for nonlinear-
ity = 0.272) between CRP levels and risk of VTE. Visual
inspection of the plot was also consistent with an approxi-
mately linear shape (Fig. 3). The combined RR of VTE for a
5 mg/l increment in CRP level was 1.23 (95% CI 1.09–1.38).
S. K. Kunutsor et al.
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Comment
Summary of main findings
Our analysis of the population-based prospective study of
middle-aged Finnish men provides no evidence of an
association between elevated CRP levels and increased risk
of developing VTE, though there was a trend towards a
positive linear relationship. Though there was no evidence
of effect modification across categories of several clinically
relevant characteristics, the associations between CRP and
VTE in older age and higher BMI groups were significant,
which was not unexpected. The meta-analysis of nine
prospective studies (including the current study) showed a
positive association between CRP levels and incident VTE
after controlling for several established risk factors and
Table 1 Baseline participant characteristics by quartiles of CRP
Overall (N = 2420) mean
(SD) or median (IQR) or n
(%)
Quartile 1 mean (SD)
or median (IQR) or n
(%)
Quartile 2 mean (SD)
median (IQR) or n
(%)
Quartile 2 mean (SD)
or median (IQR) or n
(%)
Quartile 2 mean (SD)
or median (IQR) or n
(%)
CRP (mg/l) 1.30 (0.71–2.49) 0.49 (0.36–0.60) 0.96 (0.83–1.13) 1.76 (1.53–2.09) 4.4 (3.21–6.97)
Questionnaire/prevalent conditions
Age at survey
(years)
53.2 (5.0) 52.6 (5.3) 53.2 (4.9) 53.5 (4.8) 53.6 (4.9)
Alcohol
consumption
(g/week)
75.6 (136.5) 58.7 (104.0) 66.2 (117.2) 78.6 (137.1) 98.9 (174.2)
History of
diabetes
99 (4.1) 11 (1.8) 15 (2.5) 29 (4.8) 44 (7.3)
Current
smokers
766 (31.7) 132 (21.8) 146 (24.2) 201 (33.1) 287 (47.6)
History of
hypertension
736 (30.4) 134 (22.1) 191 (31.6) 186 (30.6) 225 (37.3)
History of
CHD
620 (25.6) 103 (17.0) 139 (23.0) 159 (26.2) 219 (36.3)
Lipid
medication
16 (0.7) 3 (0.5) 1 (0.2) 5 (0.8) 7 (1.2)
Physical measurements
BMI (kg/m2) 26.9 (3.6) 25.4 (2.9) 26.6 (3.0) 27.4 (3.5) 28.2 (4.1)
SBP (mmHg) 134 (17) 131 (15) 134 (17) 136 (18) 137 (18)
DBP (mmHg) 89 (11) 87 (10) 89 (10) 89 (11) 90 (11)
Physical
activity
(kj/day)
1546 (1482) 1517 (1233) 1573 (1724) 1524 (1425) 1568 (1506)
Lipid markers
Total
cholesterol
(mmol/l)
5.92 (1.09) 5.76 (1.04) 5.93 (1.07) 6.01 (1.08) 5.98 (1.16)
HDL-C
(mmol/l)
1.30 (0.30) 1.39 (0.33) 1.30 (0.30) 1.30 (0.28) 1.21 (0.27)
Triglycerides
(mmol/l)
1.10 (0.80–1.56) 0.92 (0.70–1.27) 1.08 (0.81–1.55) 1.17 (0.85–1.61) 1.25 (0.91–1.81)
Metabolic, renal, and inflammatory markers
Fasting plasma
glucose
(mmol/l)
5.36 (1.28) 5.12 (0.64) 5.27 (1.02) 5.42 (1.35) 5.66 (1.77)
Serum
creatinine
(lmol/1)
89.6 (20.7) 89.7 (11.9) 89.7 (12.9) 89.0 (13.1) 90.0 (35.3)
GGT (U/L) 20 (15–33) 16 (12–24) 19 (14–28) 22 (16–37) 26 (18–43)
BMI body mass index, CHD coronary heart disease, CRP, C-reactive protein, DBP diastolic blood pressure, GGT gamma-glutamyltransferase,
HDL-C high-density lipoprotein cholesterol, SD standard deviation, SBP systolic blood pressure, VTE venous thromboembolism
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other potential confounders. Evidence was also lacking of
heterogeneity and publication bias among contributing
studies. Pooled estimates of studies with relevant data was
consistent with a linear dose–response relationship to the
association between CRP and VTE—characterised by a
23% increase in the risk of VTE for every 5 mg/l increment
in circulating CRP levels.
Comparison with previous studies
Though a number of prospective cohort studies have
reported on the associations of circulating levels of CRP
with subsequent risk of VTE, the majority of these studies
have demonstrated no significant evidence of any associ-
ation. The results of these previous studies are consistent
with the findings of our primary analysis, which could be
attributed to low power (low event rates) to detect an
effect. Only a limited number of studies characterized by
larger sample sizes (and comparatively higher event rates)
have so far demonstrated significant evidence of an asso-
ciation between blood circulating CRP levels and VTE risk
[17–19]. Our pooled analysis of all studies may have
therefore provided enhanced power to show statistically
significant evidence of an association between CRP levels
and VTE risk. Except for one study [49], all previous
studies did not correct for regression dilution bias; [50]
which potentially results in the underestimation of the true
association between an exposure and outcome, particularly
for cohorts with long-term follow-up. It is thus possible
that the inability of previous long-term follow-up cohort
studies to demonstrate an association between CRP and
VTE risk can be partly attributed to regression dilution
[49, 51]. For example, in the Nord-Trøndelag Health Study
(HUNT 2), a strong association was demonstrated between
CRP and VTE risk for participants who experienced VTE
within a year after blood sampling, whiles there was no
evidence of an association in participants with more than
3 years between blood sampling and VTE events [17].
Regression dilution bias can either be addressed by con-
ducting a time-varying analysis or correcting the risk
estimates using the RDR. Indeed, the recent evaluation of
the Tromsø study showed evidence of an association
between repeated measurements of CRP and VTE risk
(using time varying analysis) [49], compared to the pre-
vious analysis which employed a time-fixed analysis and
showed no evidence of an association [15]. Our repro-
ducibility substudies of CRP measurements within the
KIHD study indicated a high within-person variability in
CRP levels; which suggests that analyses using only single
baseline measurements of CRP substantially underesti-
mates the associations as we have shown.
Possible explanations for findings
An inflammatory hypothesis has been postulated in the
pathogenesis of VTE, but the evidence is limited and
Table 2 Association of serum
C-reactive protein and venous
thromboembolism
Serum CRP (mg/l) Events/total Model 1 Model 2
HR (95% CI) P value HR (95% CI) P value
Baseline CRP
Per 1 SD increase 119/2420 1.17 (0.98–1.40) 0.089 1.18 (0.97–1.44) 0.098
Q1 (0.10–0.71) 29/606 ref ref
Q2 (0.72–1.29) 29/604 1.00 (0.60–1.67) 0.998 0.97 (0.58–1.63) 0.908
Q3 (1.30–2.49) 29/607 1.10 (0.66–1.85) 0.712 1.06 (0.62–1.82) 0.825
Q4 (C2.50) 32/603 1.39 (0.84–2.30) 0.199 1.38 (0.80–2.39) 0.252
Usual CRPa
Per 1 SD increase 119/2420 1.32 (0.96–1.80) 0.089 1.34 (0.95–1.90) 0.098
Q1 (0.10–0.71) 29/606 ref ref
Q2 (0.72–1.29) 29/604 1.00 (0.40–2.47) 0.998 0.95 (0.38–2.36) 0.908
Q3 (1.30–2.49) 29/607 1.19 (0.48–2.93) 0.712 1.11 (0.43–2.85) 0.825
Q4 (C2.50) 32/603 1.79 (0.74–4.33) 0.199 1.76 (0.67–4.60) 0.252
Model 1: adjusted for age
Model 2: Model 1 plus body mass index, systolic blood pressure, history of hypertension, prevalent
coronary heart disease, smoking status, history of diabetes, total cholesterol, lipid medication, physical
activity, and gamma-glutamyltransferase
CI confidence interval, CRP C-reactive protein, HR hazard ratio, ref reference, Q quartile, SD standard
deviation
a indicates correction for within-person variability in values of CRP, that is, the extent to which an
individual’s CRP measurements vary around a long-term average value (‘‘usual CRP values’’)
S. K. Kunutsor et al.
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Age at survey (years)
< 54.4
≥ 54.4
Body mass index (kg/m2)
< 26.5
≥ 26.5
SBP (mmHg)
< 132.2
≥ 132.2
Total cholesterol (mmol/l)
< 5.85
≥ 5.85
GGT (U/L)
< 21
≥ 21
History of diabetes
No
Yes
Smoking status
Non-smokers
Current smokers
History of hypertension
No
Yes
Prevalent CHD
No
Yes
Subgroup
1,282
1,138
1,210
1,210
1,213
1,207
1,216
1,204
1,218
1,202
2,321
99
1,654
766
1,684
736
1,800
620
No. of participants
66
53
59
60
64
55
57
62
66
53
115
4
95
24
86
33
87
32
No. of VTE cases
1.07 (0.82, 1.39)
1.36 (1.03, 1.79)
1.15 (0.87, 1.50)
1.32 (1.01, 1.72)
1.17 (0.90, 1.52)
1.19 (0.90, 1.58)
1.31 (1.01, 1.69)
1.06 (0.80, 1.40)
1.22 (0.95, 1.58)
1.17 (0.87, 1.56)
1.19 (0.97, 1.46)
1.05 (0.39, 2.85)
1.20 (0.95, 1.50)
1.14 (0.77, 1.70)
1.21 (0.97, 1.52)
1.10 (0.75, 1.60)
1.16 (0.92, 1.46)
1.26 (0.88, 1.79)
HR (95% CI)
.192
.454
.928
.258
.802
.811
.843
.645
.696
P-value*
1.25 .5 .75 1.5 2.5 5
HR (95% CI) per 1 SD higher log baseline CRP levels
Fig. 1 Hazard ratios for baseline values of C-reactive protein and
venous thromboembolism risk by several participant level character-
istics. Hazard ratios are adjusted for age, body mass index, SBP,
history of hypertension, prevalent CHD, smoking status, history of
diabetes, total cholesterol, lipid medication, physical activity, and
GGT; CHD, coronary heart disease; CI, confidence interval; CRP,
C-reactive protein; GGT, gamma-glutamyltransferase; HR, hazard
ratio; SD, standard deviation; SBP, systolic blood pressure; VTE,
venous thromboembolism; *, P value for interaction; cut-offs used for
age, body mass index, SBP, total cholesterol, and GGT are median
values
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Fig. 2 Prospective studies of C-reactive protein and risk of venous
thromboembolism. The summary estimates presented were calculated
using random effects models; relative risks are reported per 1 standard
deviation (SD) increase in C-reactive protein levels; size of data
markers are proportional to the inverse of the variance of the relative
ratio; CI, confidence interval (bars); RR, relative risk; VTE, venous
thromboembolism
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unclear. Though inflammation as well as increased CRP
levels are well known to increase the risk of
atherothrombosis [13, 52] and may also promote hyper-
coagulable states, it is still uncertain if inflammation
actually increases the risk of VTE. The overall findings
from the current study lend some support to this inflam-
matory hypothesis. Indeed, several other inflammatory
markers such as the interleukins and tumour necrosis factor
alpha have been shown to be associated with VTE [53, 54].
Statins are known to decrease CRP levels (by up to 60%)
independent of reductions in levels of low-density
lipoprotein [55] and it has also been shown in both
observational cohort as well as clinical intervention studies
that statin treatment is associated with a reduction in risk of
VTE [56, 57]. The beneficial effect of statins on VTE has
been attributed to its anti-inflammatory effects [58].
Though statins also possess antithrombotic properties [59]
which may explain the protective effect on VTE; it has also
been postulated that the antithrombotic effects of statins are
likely to be linked to their anti-inflammatory properties
[60]. There have also been suggestions that atherosclerotic
disease is an underlying condition and precedes the
development of VTE [7]; however, evidence on the con-
trary suggests this is not the case [61]. The aetiopathogenic
pathways underlying the association between CRP and
VTE remain elusive, therefore mechanistic studies are
needed to clarify the uncertainties. Collectively, the present
study establishes an observational linear dose–response
association to the link between CRP and VTE risk. Whe-
ther elevated CRP is a direct cause of VTE or just a risk
marker remains unclear. However, Zacho and colleagues
using a Mendelian randomization design have shown that
genetically elevated CRP is not associated with VTE risk
[16]. In another study, genetic polymorphisms that increase
CRP levels were shown not to be associated with VTE risk
[62]. Taking the evidence together, it can be argued that
increased CRP is unlikely to have a causal relevance to
VTE, but rather be a risk marker of VTE.
Implications of findings
C-reactive protein is an independent risk marker for CVD
and may be of value in the discrimination and reclassifi-
cation of individuals at risk for CVD [63]. Cardiovascular
disease and VTE are closely linked conditions [7–9], share
common risk factors [10], and may have common patho-
physiological mechanisms; the current findings suggest that
CRP may also play a role in the development of VTE.
Large-scale studies are needed to replicate this association
and investigate the potential relevance of CRP in VTE
prevention. If CRP is demonstrated to have a role in pre-
venting VTE, information on CRP levels may be of
immense clinical benefit such as guiding the dosage and
duration of anticoagulant therapy. Studies are also needed
to establish if the protective effect of statin treatment on
VTE risk is due to its CRP lowering effects.
Strengths and limitations
Our analysis had the advantage of utilizing a large-scale
population-based prospective cohort design with selection
of men who were nationally representative; involved a high
response rate with no loss to follow-up; the long follow-up
period of over 20 years; and the comprehensive analysis
with adjustment for a broad panel of risk factors and
potential confounders as well stratified analyses by several
clinical relevant characteristics. Repeat measurements of
CRP made within a random subset of individuals over time
after baseline were available, which enabled correction for
the extent of within-person variability in CRP over the long
period of follow-up. Ideally, it would have been more
appropriate to conduct a time-varying analysis as correc-
tions using the RDR have been suggested to result in
overcorrection of the risk estimates if the relationship
between the exposure and outcome is not short term [64].
Indeed, it has recently been shown that corrections of the
association between several atherosclerotic risk factors and
VTE risk using RDRs consistently overestimated the risk
estimates compared with time-varying analysis [51]. The
same study showed that risk estimates for VTE based on
baseline measurements (time-fixed analyses) corresponded
well with those of time-varying analyses. We were unable
to perform a time-varying analysis to allow for changes in
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Fig. 3 Dose-response relation between C-reactive protein and risk of
venous thromboembolism for pooled results of studies providing
relevant data. Adjusted relative risks and 95% confidence intervals
(CIs dashed lines) are reported. Data were modeled with restricted
cubic splines with 3 knots in random-effects dose–response models.
The median value (0.30 mg/l) of the lowest reference range was used
to estimate all relative risks. The vertical axes are on log scales. The
following studies reported relevant data to model the dose–response
relationship between C-reactive protein and venous thromboem-
bolism risk [15–18]
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CRP during follow-up, as we did not have the relevant
data. The current risk estimate should therefore be inter-
preted with caution as there is a possibility that the true
estimate lies between that of the time-fixed analysis with-
out and with correction for regression dilution. Other
strengths of the current study include the ability to conduct
a pooled analysis of previous studies including the current
study, which enhanced power to reliably assess the nature,
magnitude, and shape of the association. In our pooled
analysis, there was no evidence of heterogeneity or publi-
cation bias among contributing studies. There were limi-
tations which deserve mention and include: (1) inability to
generalize the findings to women and other population; (2)
we had data on only total VTE which precluded the ability
to conduct subgroup analyses of unprovoked or provoked
VTE outcomes; (3) because of lack of appropriate data, we
were unable to account for incident cancer as a time-
varying covariate as this could partly account for the
association between CRP and VTE; (4) inability to fully
examine the impact of adjustment for potential con-
founders, because the review was based on variably
adjusted data reported in the published literature; however,
majority of included studies adjusted for major con-
founders; and (5) our dose–response analysis was limited to
datapoints reported by only four studies.
Conclusions
C-reactive protein was only modestly associated with VTE
risk in this middle-aged Caucasian population, which may
be attributed to the low event rate. Pooled evidence which
enhanced statistical power, however, suggests that
increased circulating CRP is associated with greater VTE
risk and consistent with a linear dose–response relation-
ship. Further research is needed to evaluate any potential
relevance of CRP in VTE prevention.
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